Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Veterinary medicine
Name of medicinal product: Advocate täpilahus suurtele koertele
Active substances:
Moxidectin+Imidacloprid
Estonian, English, Latin
ATC code: QP54AB81
Dosage form: spot-on solution
Strength: 62,5mg+250mg 2.5ml
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Labelling:  
Indication: For dogs suffering from, or at risk from, mixed parasitic infections: • the treatment and prevention of flea infestation (Ctenocephalides felis), • the treatment of biting lice (Trichodectes canis), • the treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis), • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis), • the treatment of circulating microfilariae (Dirofilaria immitis), • the treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens) • the prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens), • the reduction of circulating microfilariae (Dirofilaria repens), • the prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum), • the treatment of Angiostrongylus vasorum and Crenosoma vulpis, • the prevention of spirocercosis (Spirocerca lupi), • the treatment of Eucoleus (syn. Capillaria) boehmi (adults), • the treatment of the eye worm Thelazia callipaeda (adults), • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis). The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Safety features: No
Marketing authorization holder: Elanco Animal Health GmbH 
Marketing authorization number: EU/2/03/039 
Marketing authorization issued on: April 2, 2003 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1212163  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 3TK  Prescription      28.03.2024     
1212174  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 4TK  Prescription           
1212185  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 6TK  Prescription           
1306617  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 21TK  Prescription           
1306628  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 42TK  Prescription           
1605989  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 1TK  Prescription           
1605990  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 2TK  Prescription           
1606003  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 9TK  Prescription           
1606014  Advocate täpilahus suurtele koertele  spot-on solution  62,5mg +250mg 2.5ml 2.5ml 12TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere